All articles by Hasini Devarasetti

Hasini Devarasetti

Aptose Biosciences begins subject dosing in AML therapy trial

The trial will assess the pharmacodynamics, tolerability, safety, and pharmacokinetics of HM43239 in R/R AML patients.

FDA clears Escient’s IND for mast cell mediated disorders therapy trial

The Phase I study will assess the pharmacokinetics, tolerability, and safety of EP262 in healthy volunteers.

Central IRB approves Skye Bioscience’s SBI-100 OE trial

The trial will evaluate SBI-100 OE in primary open angle glaucoma or ocular hypertension patients.

Marengo Therapeutics begins subject dosing in cancer therapy trial

The trial will assess the tolerability, preliminary clinical activity, and safety of STAR0602 as a monotherapy.

XyloCor reports positive data from refractory angina gene therapy trial

Participants treated with XC001 showed improvements in ischaemic burden and total exercise duration.

BioCryst starts subject enrolment in trial of hereditary angioedema therapy

The trial will assess the safety and pharmacokinetics of Orladeyo in paediatric HAE patients.

AC Immune reports positive data from Alzheimer’s disease vaccine trial

At week six, the ACI-24.060 vaccine elicited an anti-Abeta antibody response in ABATE’s first, low dose cohort of AD patients.

Small Pharma’s depressive disorder therapy trial meets primary goal

The trial assessed the safety and efficacy of IV SPL026 with supportive therapy in 34 MDD patients.

Aculys Pharma starts Phase III EDS therapy trial

The trial will assess pitolisant’s efficacy and safety in Japanese OSAS patients who are complaining of EDS.

Benitec Biopharma begins OPMD subject enrolment

The NH study will enable the characterisation of OPMD patient disposition at baseline.